B B Zhang

Summary

Affiliation: Merck Research Laboratories
Country: USA

Publications

  1. ncbi Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma
    B Zhang
    Department of Molecular Endocrinology, Merck Research Laboratories, Rahway, New Jersey 07065, USA
    J Biol Chem 271:31771-4. 1996
  2. ncbi Small molecule insulin receptor activators potentiate insulin action in insulin-resistant cells
    M Li
    University of California at San Francisco, Mount Zion Medical Center, San Francisco, California 94143-1616, USA
    Diabetes 50:2323-8. 2001
  3. ncbi Discovery of a small molecule insulin mimetic with antidiabetic activity in mice
    B Zhang
    Department of Molecular Endocrinology, Merck Research Laboratories, R80W250, Post Office Box 2000, Rahway, NJ 07065, USA
    Science 284:974-7. 1999
  4. ncbi New approaches in the treatment of type 2 diabetes
    B B Zhang
    Department of Molecular Endocrinology, Merck Research Laboratories, Rahway, NJ 07065, USA
    Curr Opin Chem Biol 4:461-7. 2000
  5. ncbi AMPK: an emerging drug target for diabetes and the metabolic syndrome
    Bei B Zhang
    Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07065, USA
    Cell Metab 9:407-16. 2009
  6. ncbi Discovery of a small molecule insulin receptor activator
    G M Salituro
    Department of Natural Product Drug Discovery, Merck Research Laboratories, Rahway, New Jersey 07065, USA
    Recent Prog Horm Res 56:107-26. 2001
  7. ncbi Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice
    J Mu
    Merck, RY80N A58, 126 East Lincoln Avenue, Rahway, NJ, USA
    Diabetologia 54:2381-91. 2011
  8. ncbi Discovery of a potent, highly selective, and orally efficacious small-molecule activator of the insulin receptor
    K Liu
    Merck Research Laboratories, P O Box 2000, Rahway, New Jersey 07065, USA
    J Med Chem 43:3487-94. 2000
  9. ncbi AMPK activators--potential therapeutics for metabolic and other diseases
    G Zhou
    Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ, USA
    Acta Physiol (Oxf) 196:175-90. 2009
  10. ncbi Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia
    S L Conarello
    Laboratory Animal Resources, Merck Research Laboratories, Rahway, NJ, USA
    Diabetologia 50:142-50. 2007

Collaborators

Detail Information

Publications13

  1. ncbi Insulin- and mitogen-activated protein kinase-mediated phosphorylation and activation of peroxisome proliferator-activated receptor gamma
    B Zhang
    Department of Molecular Endocrinology, Merck Research Laboratories, Rahway, New Jersey 07065, USA
    J Biol Chem 271:31771-4. 1996
    ..2) PPARgamma is phosphorylated in vivo by insulin stimulation or activation of the MAP kinase pathway. 3) MAP kinase is an important mediator of cross-talk between insulin signal transduction pathways and PPARgamma function...
  2. ncbi Small molecule insulin receptor activators potentiate insulin action in insulin-resistant cells
    M Li
    University of California at San Francisco, Mount Zion Medical Center, San Francisco, California 94143-1616, USA
    Diabetes 50:2323-8. 2001
    ..In summary, these two classes of IR activators selectively increased IR function in a variety of insulin-resistant cell lines...
  3. ncbi Discovery of a small molecule insulin mimetic with antidiabetic activity in mice
    B Zhang
    Department of Molecular Endocrinology, Merck Research Laboratories, R80W250, Post Office Box 2000, Rahway, NJ 07065, USA
    Science 284:974-7. 1999
    ..These results demonstrate the feasibility of discovering novel insulin receptor activators that may lead to new therapies for diabetes...
  4. ncbi New approaches in the treatment of type 2 diabetes
    B B Zhang
    Department of Molecular Endocrinology, Merck Research Laboratories, Rahway, NJ 07065, USA
    Curr Opin Chem Biol 4:461-7. 2000
    ....
  5. ncbi AMPK: an emerging drug target for diabetes and the metabolic syndrome
    Bei B Zhang
    Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ 07065, USA
    Cell Metab 9:407-16. 2009
    ..Activation of AMPK by pharmacological agents presents a unique challenge, given the complexity of the biology, but holds a considerable potential to reverse the metabolic abnormalities associated with type 2 diabetes...
  6. ncbi Discovery of a small molecule insulin receptor activator
    G M Salituro
    Department of Natural Product Drug Discovery, Merck Research Laboratories, Rahway, New Jersey 07065, USA
    Recent Prog Horm Res 56:107-26. 2001
    ..Thus, DMAQ-B1 represents the first orally active insulin-mimetic agent. Pharmaceutical intervention aimed at augmenting IR function ultimately may prove beneficial as a novel therapeutic option in patients with diabetes...
  7. ncbi Chronic treatment with a glucagon receptor antagonist lowers glucose and moderately raises circulating glucagon and glucagon-like peptide 1 without severe alpha cell hypertrophy in diet-induced obese mice
    J Mu
    Merck, RY80N A58, 126 East Lincoln Avenue, Rahway, NJ, USA
    Diabetologia 54:2381-91. 2011
    ..Antagonism of the glucagon receptor (GCGR) represents a potential approach for treating diabetes. Cpd-A, a potent and selective GCGR antagonist (GRA) was studied in preclinical models to assess its effects on alpha cells...
  8. ncbi Discovery of a potent, highly selective, and orally efficacious small-molecule activator of the insulin receptor
    K Liu
    Merck Research Laboratories, P O Box 2000, Rahway, New Jersey 07065, USA
    J Med Chem 43:3487-94. 2000
    ..Results from additional studies with compound 2h, aimed at evaluating classical quinone-related phenomena, provided sufficient grounds for optimism to allow more extensive toxicologic evaluation...
  9. ncbi AMPK activators--potential therapeutics for metabolic and other diseases
    G Zhou
    Department of Metabolic Disorders, Merck Research Laboratories, Rahway, NJ, USA
    Acta Physiol (Oxf) 196:175-90. 2009
    ..Activators of AMPK that target selected tissues hold potential as novel therapeutics for diseases in which altered energy metabolism contributes to aetiology...
  10. ncbi Glucagon receptor knockout mice are resistant to diet-induced obesity and streptozotocin-mediated beta cell loss and hyperglycaemia
    S L Conarello
    Laboratory Animal Resources, Merck Research Laboratories, Rahway, NJ, USA
    Diabetologia 50:142-50. 2007
    ..The goal of the current research was to further investigate the role of glucagon signalling in metabolic control and glucose homeostasis...
  11. ncbi RNAi-mediated germline knockdown of FABP4 increases body weight but does not improve the deranged nutrient metabolism of diet-induced obese mice
    R Yang
    Department of Metabolic Disorders Diabetes, Merck Research Laboratories, Rahway, NJ 07065, USA
    Int J Obes (Lond) 35:217-25. 2011
    ..To investigate the impact of reduced adipocyte fatty acid-binding protein 4 (FABP4) in control of body weight, glucose and lipid homeostasis in diet-induced obese (DIO) mice...
  12. ncbi Modulation of insulin signalling by insulin sensitizers
    G Jiang
    Metabolic Disorders - Diabetes, Merck Research Laboratories, PO Box 2000, Rahway, NJ 07065, USA
    Biochem Soc Trans 33:358-61. 2005
    ..Taken together, the results suggest that IRS1 inhibitory serine phosphorylation is a key component of insulin resistance and its reversal may be physiologically relevant to insulin sensitization in vivo...
  13. ncbi Insulin action in cultured human skeletal muscle cells during differentiation: assessment of cell surface GLUT4 and GLUT1 content
    L Al-Khalili
    Department of Surgical Science, Karolinska Institutet, 17177 Stockholm, Sweden
    Cell Mol Life Sci 60:991-8. 2003
    ..05) increased glucose uptake and glycogen synthesis. Thus, cultured myotubes are a useful tool to facilitate biological and molecular validation of novel pharmacological agents aimed to improve glucose metabolism in skeletal muscle...